Geron (NASDAQ:GERN – Get Free Report) and Evogene (NASDAQ:EVGN – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.
Earnings and Valuation
This table compares Geron and Evogene”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Geron | $183.88 million | 3.41 | -$83.50 million | ($0.08) | -12.18 |
| Evogene | $3.85 million | 0.84 | -$8.48 million | ($0.91) | -0.41 |
Evogene has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and recommmendations for Geron and Evogene, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Geron | 1 | 2 | 3 | 0 | 2.33 |
| Evogene | 1 | 0 | 0 | 0 | 1.00 |
Geron presently has a consensus target price of $3.75, suggesting a potential upside of 284.93%. Given Geron’s stronger consensus rating and higher probable upside, equities analysts plainly believe Geron is more favorable than Evogene.
Volatility & Risk
Geron has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Evogene has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500.
Profitability
This table compares Geron and Evogene’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Geron | -23.04% | -16.29% | -6.82% |
| Evogene | -694.18% | -156.53% | -86.80% |
Institutional & Insider Ownership
73.7% of Geron shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 1.7% of Geron shares are owned by company insiders. Comparatively, 7.4% of Evogene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Geron beats Evogene on 10 of the 13 factors compared between the two stocks.
About Geron
Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapies for blood disorders and cancers. Its lead product, Rytelo (imetelstat), is a telomerase inhibitor approved in the United States to treat certain adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. Geron continues to develop imetelstat for potential use in other hematologic conditions. The company was founded in 1990 and is headquartered in Foster City, California.
About Evogene
Evogene Ltd. (NASDAQ: EVGN) is an Israel-based computational biology company that develops technologies and products designed to improve human health, agriculture and sustainability. The company uses artificial intelligence, machine learning and biological data analysis through its Computational Predictive Biology platform to identify and develop solutions based on biological mechanisms. Evogene has built a portfolio of subsidiaries and business units focused on areas including agricultural biologicals, crop protection, microbiome-based therapeutics and medical cannabis.
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.
